MigraineMind research summary
Implementing Intravenous Eptinezumab in Routine Migraine Care: A Mixed-Methods Study of Patient and Healthcare Professional Perspectives.
Neurol Ther | 2026
Observational studySummary
Eptinezumab is a new treatment for migraine prevention. It is given through an intravenous infusion every three months. This study focused on how patients and healthcare professionals feel about eptinezumab. Researchers interviewed 20 patients and 10 healthcare professionals. They wanted to understand the benefits and challenges of using this treatment. Patients reported a significant reduction in headache days. Monthly headache days dropped from 18.5 to 2.5 over six months. Healthcare professionals also shared their experiences with eptinezumab. They noted that patients generally responded well to the treatment. However, some challenges were identified, including the need for better education about the drug. Overall, eptinezumab shows promise for improving migraine care. More research is needed to address the challenges and improve implementation in routine practice. Understanding these perspectives can help enhance the treatment experience for future patients. Clinical relevance: This study highlights eptinezumab's effectiveness in reducing migraine days, emphasizing the need for better education and support for patients and healthcare professionals in its use.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.
